+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

First clinical trial of specific IKACh blocker shows no reduction in atrial fibrillation burden in patients with paroxysmal atrial fibrillation: pacemaker assessment of BMS 914392 in patients with paroxysmal atrial fibrillation



First clinical trial of specific IKACh blocker shows no reduction in atrial fibrillation burden in patients with paroxysmal atrial fibrillation: pacemaker assessment of BMS 914392 in patients with paroxysmal atrial fibrillation



Europace 18(3): 340-346



To assess the efficacy of BMS 914392 on atrial fibrillation (AF) burden reduction in 20 patients with pacemakers and paroxysmal atrial fibrillation (PAF). BMS 914392 is a potent, selective, oral inhibitor of the IKACh current and has been shown to suppress AF, whilst having no effect on the ventricular refractory period. This is the first efficacy study of BMS 914392 in patients with PAF. The study was a four-way, crossover, double-blind design. A total of 20 patients with PAF and dual-chamber pacemakers were recruited. The pacemakers allowed beat-to-beat monitoring. Anti-arrhythmic drugs were withdrawn. Patients received low-dose (10 mg OD), medium-dose (10 mg TDS), and high-dose (20 mg TDS) BMS 914392 or placebo for 3 weeks before being crossed to the next phase. Patients underwent a washout period, four treatment phases and a final washout phase. Atrial fibrillation burden was downloaded from their pacemakers at the end of each study phase. BMS 914392 did not reduce AF burden when compared with placebo (10 mg OD P = 0.56, 10 mg TDS P = 0.22, 20 mg TDS P = 0.23). Heart rate and corrected QT (QTc) were not affected by BMS 914392. Adverse event (AE) rates did not differ from placebo in any of the treatment groups, with no serious AEs recorded. BMS 914932 has not been shown to reduce AF burden in patients with PAF and pacemakers using beat-to-beat pacemaker monitoring throughout the study. BMS 914392 was well tolerated and did not affect QTc or reduce heart rate. Clinicaltrials.gov: NCT01356914.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057880441

Download citation: RISBibTeXText

PMID: 26462707

DOI: 10.1093/europace/euv263


Related references

Atrial fibrillation suppression reduces atrial fibrillation burden on patients with paroxysmal atrial fibrillation and class 1 2 pacemaker indication The OASES Study. European Heart Journal 24(Abstract Suppl.): 369, August-September, 2003

Relevance of electrical remodeling in human atrial fibrillation: results of the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial mechanisms of atrial fibrillation study. Circulation. Arrhythmia and Electrophysiology 5(4): 626-631, 2012

Can common-type atrial flutter be a sign of an arrhythmogenic substrate in paroxysmal atrial fibrillation? Clinical and ablative consequences in patients with coexistent paroxysmal atrial fibrillation/atrial flutter. Circulation 116(24): 2786-2792, 2007

Stroke type and severity in patients with subclinical atrial fibrillation: An analysis from the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial (ASSERT). American Heart Journal 201: 160-163, 2018

Combined assessment of left atrial volume parameters for predicting recurrence of atrial fibrillation following pulmonary vein isolation in patients with paroxysmal atrial fibrillation. Echocardiography 36(5): 862-869, 2019

Development of chronic atrial fibrillation following atrioventricular junction ablation and pacemaker implantation in patients with paroxysmal atrial fibrillation. Canadian Journal of Cardiology 16(Suppl. F): 138F, 2000

Impact of Complete Versus Incomplete Circumferential Lines Around the Pulmonary Veins During Catheter Ablation of Paroxysmal Atrial Fibrillation: Results From the Gap-Atrial Fibrillation-German Atrial Fibrillation Competence Network 1 Trial. Circulation. Arrhythmia and Electrophysiology 9(1): E003337, 2016

Development of chronic atrial fibrillation following his ablation and pacemaker implantation in patients with paroxysmal atrial fibrillation. Circulation 102(18 Suppl.): II 800, 2000

Different patterns of atrial activation in idiopathic atrial fibrillation: Simultaneous multisite atrial mapping in patients with paroxysmal and chronic atrial fibrillation. Journal of the American College of Cardiology 37(2): 534-541, 2001

Supernormal atrial conduction and its relation to atrial vulnerability and atrial fibrillation in patients with sick sinus syndrome and paroxysmal atrial fibrillation. American Heart Journal 128(1): 88-95, 1994

Echocardiographic predictors of frequency of paroxysmal atrial fibrillation (AF) and its progression to persistent AF in hypertensive patients with paroxysmal AF: results from the Japanese Rhythm Management Trial II for Atrial Fibrillation (J-RHYTHM II Study). Heart Rhythm 8(12): 1831-1836, 2011

Echocardiographic predictors of frequency of paroxysmal atrial fibrillation AF and its progression to persistent AF in hypertensive patients with paroxysmal AF results from the Japanese Rhythm Management Trial II for Atrial Fibrillation J-RHYTHM II S. 2011

ASymptomatic atrial fibrillation and Stroke Evaluation in pacemaker patients and the atrial fibrillation Reduction atrial pacing Trial (ASSERT). American Heart Journal 152(3): 442-447, 2006

The relationship between right ventricular pacing and atrial fibrillation burden and disease progression in patients with paroxysmal atrial fibrillation: the long-MinVPACE study. Europace 13(6): 815-820, 2011

Effect of combined spironolactone-β-blocker ± enalapril treatment on occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial fibrillation (SPIR-AF study). American Journal of Cardiology 106(11): 1609-1614, 2010